Medindia

X

FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

Tuesday, February 16, 2010 General News J E 4
Advertisement

Quark Pharmaceuticals, Inc.

The Ruth Group (investors / media)

Juliana Friedman

Sara Pellegrino / Janine McCargo

+972 89 30 5111

(646) 536-7002 / 7033

jfriedman@quarkpharma.com

spellegrino@theruthgroup.com

jmccargo@theruthgroup.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Alexza Pharmaceuticals to Host 2010 Investor/Analy...
S
The Skin Cancer Foundation Stamps jane iredale - T...